The improvement of patients under thioridazine therapy is considered significant in view of the severity and chronicity of their illness and their failure to respond to all previous therapies. An important advantage of thioridazine over chlorpromazine and trifluoperazine is the low incidence of side effects. Because of the results obtained, we feel that further trial of thioridazine (Mellaril) on regressed patients is warranted.Abstract Teaser